Mauricio Drummond, Jr.

https://assets.montefioreeinstein.org/profiles/images/Drummond_Jr_Mauricio_MD_2x.jpg

First Name

Mauricio

Last Name

Drummond, Jr.

NPI

1801450176

Faculty ID

17445

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Drummond’s clinical focus is in pediatric sports medicine with a special focus on knee pathology.

Research Focus

Dr. Drummond’s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears

Elsevier Profile

EMR ID

123889

Biography

<p>Mauricio Drummond Jr., MD, is an attending surgeon and Assistant Professor, Pediatrics and Orthopedic Surgery at Children&rsquo;s Hospital at Montefiore. Dr. Drummond&rsquo;s clinical focus is in pediatric sports medicine with a special focus on knee pathology. His interests include pediatric orthopedic surgery, complex pediatric and adolescent sports medicine, ACL, PCL and multiligament knee injuries, discoid meniscus, meniscus transplantation, patellofemoral instability, trochlear dysplasia, cartilage preservation and pediatric trauma and limb deformities.</p><p>In 1996, Dr. Drummond earned his Doctor of Medicine from Universidade Federal do Rio de Janeiro (Federal University of Rio de Janeiro) in Rio de Janeiro, Brazil. He completed his residency training at the same institution, and practiced as a knee specialist for more than 13 years in Brazil. In 2018, he came to the United States, completing an orthopedic surgery research fellowship at Cleveland Clinic Foundation in 2019 and an orthopedic sports medicine fellowship at the University of Pittsburgh Medical Center in 2020. He continued his postdoctoral training, completing his pediatric orthopedics and limb deformity fellowship at Montefiore Medical Center in 2021 and his pediatric orthopedics fellowship at Connecticut Children&rsquo;s Medical Center in 2022.</p><p>Dr. Drummond&rsquo;s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears. He has shared his work nationally and internationally through peer-reviewed journals and podium and poster presentations. He is also a reviewer for the <em>American Journal of Sports Medicine</em>.</p><p>Dr. Drummond is a member of several professional organizations including the International Society of Arthroscopy and Knee Orthopaedic Sports Medicine (ISAKOS), the American Orthopaedic Society for Sports Medicine (AOSSM), the Pediatric Orthopaedic Society of North America (POSNA) and the Pediatric Research in Sports Medicine Society (PRiSM).</p>

Is Open Scheduling

Off

Rui Yang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Yang_Rui_MD_420x504.jpg

First Name

Rui

Last Name

Yang

NPI

1215280532

Faculty ID

9892

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopaedic residency at Peking University People&rsquo;s Hospital in Beijing, China.&nbsp; Following his training in China, he came to the United States where he earned a Master&rsquo;s degree in Biological Sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopaedic surgery residency at the University of Texas, in Houston and then he did a fellowship in Orthopaedic Oncology at Memorial Sloan-Kettering Cancer Center.</p>
<p>Dr. Yang specializes in the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system. A multidisciplinary approach is emphasized in his practice. He performs surgery to remove the tumor fom the limb and pelvis, and rebuild them using techniques tailored for each individual patient. Dr. Yang is also interested in treating metastatic bony lesions originating from other parts of the body.</p>
<p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumorigenesis of osteosarcoma and the genetic profile of the tumors as comparison to its normal counterpart tissues.&nbsp; He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, as well as novel strategies to overcome it in collaboration with the pediatric sarcoma teams.</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p>1. Peer-reviewed Papers</p>
<p>1) <strong>Yang, R.</strong>, Piperdi, S.,&nbsp; Zhang, Y., Neophytou, N., Zhu, W., Hoang, B.H., Mason, G., Geller, D., Dorfman, H,, Healey, J.H., Phinney, D.G., and Gorlick, R. Transcriptional Profiling Identifies the Signaling Axes of the Insulin Growth Factor and the Transforming Growth Factor-beta as involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res. 2015. PMID: 26463566</p>
<p>2) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.,</strong> Linkov, I., Sowers, R., DiResta, G.R., Gorlick, R., Healey, J.H.&nbsp;Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma <a href="http://www.ncbi.nlm.nih.gov/pubmed/20052438">.</a&gt; Ann Acad Med Singapore. 2009; 38(12):1041-7. PMID: 20052438</p>
<p>3) Li, N., <strong>Yang, R.</strong>, Zhang, W., Dorfman, H., Rao, P., and Gorlick, R. Genetically Transforming Human Mesenchymal Stem Cells to Sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer. 2009; 115(20): 4795-806. PMID: 19593798</p>
<p>4) <strong>Yang, R</strong>., Piperdi, S., and Gorlick, R. Activation of the RAF/MEK/ERK pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res. 2008;14(20): 6396-404. PMID: 18927278</p>
<p>5) <strong>Yang, R.</strong>, Qin, J., Hoang, B.H., Healey, J.H., and Gorlick, R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 2008;466:2046-51. PMID: 18528741</p>
<p>6) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.</strong>, Linkov, I., Sowers, R., Diresta, G.R., Gorlick, R., and Healey, J.H. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 2008;26:1-6. PMID: 18473395</p>
<p>7) <strong>Yang, R.</strong>, Li, W.W., Hoang, B.H., Kim, H., Banerjee, D., Kheradpour, A., Healey, J.H., Meyers, P.A., Bertino, J.R., and Gorlick, R. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008;8:124. PMID: 18452618</p>
<p>8) <strong>Yang, R.</strong>, Kolb, E.A., Qin, J., Chou, A., Sowers, R., Hoang, B., Healey, J.H., Huvos, A.G., Meyers, P.A. and Gorlick, R. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007;13:2557-67. PMID: 17473184</p>
<p>9) <strong>Yang, R.</strong>, Hoang, B.H., Kubo, T., Kawano, H., Chou, A., Sowers, R., Huvos, A.G., Meyers, P.A., Healey, J.H. and Gorlick, R. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007;121:943-54. PMID: 17410535</p>
<p>10) Laverdiere, C., Hoang, B.H., <strong>Yang, R.</strong>, Sowers, R., Qin, J., Meyers, P.A., Huvos, A.G., Healey, J.H. and Gorlick, R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-7. PMID: 15814634</p>
<p>11) Nathan, S.S., DiResta, G.R., Casas-Ganem, J.E., Hoang, B.H., Sowers, R., <strong>Yang, R.</strong>, Huvos, A.G., Gorlick, R. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005;11:2389-97. PMID: 15788690</p>
<p>12) Flintoff, W.F., Sadlish, H., Gorlick, R., <strong>Yang, R.</strong>, Williams, F.M. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 2004;1690:110-7. PMID: 15469899</p>
<p>13) Hoang, B.H., Kubo, T., Healey, J.H., <strong>Yang, R.</strong>, Nathan, S.S., Kolb, E.A., Mazza, B., Meyers, P.A. and Gorlick, R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64:2734-9. PMID: 15087387</p>
<p>14) Hoang, B.H., Kubo, T., Healey, J.H., Sowers, R., Mazza, B., <strong>Yang, R.</strong>, Huvos, A.G., Meyers, P.A. and Gorlick, R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106-11. PMID: 14735475</p>
<p>15) <strong>Yang, R.</strong>, Sowers, R., Mazza, B., Healey, J.H., Huvos, A., Grier, H., Bernstein, M., Beardsley, G.P., Krailo, M.D., Devidas, M., Bertino, J.R., Meyers, P.A. and Gorlick, R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003;9:837-44. PMID: 12576457</p>
<p>&nbsp;</p>
<p>2. Book Chapters</p>
<p align="left">1) Orthopedic Oncology. Editor: Xun, W.P., Feng, C.H. People&rsquo;s Military Medical Publisher.</p>
<p>(ISBN: 7-80157-159-2), 2001.</p>
<p>2) Review of Surgery: A Guiding Book for Medical Students. Section of Orthopedics. Editor: Jiang, B.G. Beijing Medical University Publisher.&nbsp; (ISBN: 7-81034-946-5), 1999.</p>

EMR ID

78569

Biography

<p>Dr. Yang is a fellowship-trained orthopedic surgeon recognized for his multidisciplinary approach to the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors. He also serves as an Assistant Professor at our Albert Einstein College of Medicine.</p><p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopedic residency at Peking University People?s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a master?s degree in biological sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopedic surgery residency at the University of Texas, in Houston, followed by a fellowship in orthopedic oncology at Memorial Sloan-Kettering Cancer Center.</p><p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.</p>

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Victoria Vapnyar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/dd685560-3db5-11ec-b813-25aca5adcea8.jpg

First Name

Victoria

Last Name

Vapnyar

NPI

1740556133

Faculty ID

17135

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

101619

Is Open Scheduling

Off

Henry Michael Ushay

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ushay_Michael_MD_420x504.jpg

First Name

Henry

Last Name

Ushay

NPI

1558332007

Faculty ID

10275

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric critical care medicine with a special emphasis on respiratory failure; shock resuscitation; cardiac intensive care; intensive care of pediatric oncology patients; extracorporeal support for children with respiratory and cardiovascular failure

Research Focus

Leadership and direction of the 16-bed Pediatric Critical Care Unit of The Children&rsquo;s Hospital at Montefiore; improving medication safety; respiratory physiology; advances in the management of respiratory failure in children; shock; medical ethics

Elsevier Profile

EMR ID

4763

Biography

<p>Dr. Ushay is Professor of Clinical Pediatrics in the Albert Einstein College of Medicine. He is a Fellow of the American Academy of Pediatrics as well as a Fellow of the American College of Critical Care Medicine. </p><p>After obtaining a PhD in Chemistry from Columbia University, Dr. Ushay received his MD from UMDNJ-New Jersey Medical School and completed a Pediatrics residency in the Montefiore-Jacobi-Einstein program. After serving as Chief Resident and a Fellow in Pediatric Pulmonology at Montefiore, he completed a Pediatric Critical Care Fellowship at New York Hospital/Cornell Medical Center in 1993. He was a faculty member at NewYork-Presbyterian and Memorial Sloan-Kettering Hospitals from 1993 to 2005, and he served as Pediatric Critical Care Medicine Fellowship Program Director and Medical Director of the Pediatric Observation Unit at Memorial Sloan-Kettering Cancer Center. </p><p>In 2005 Dr. Ushay became Director of the Pediatric Critical Care Unit in The Children&rsquo;s Hospital at Montefiore. Dr. Ushay is involved in increasing pediatric ICU surge capacity through the New York City Pediatric Disaster Coalition, serving on its Central Leadership Council and teaching the Pediatric Fundamental Critical Care Support Course. Through the National Institute of Child Health and Human Development, Dr. Ushay works on employing medical countermeasures safely for children in the event of chemical, biological or radiological disaster. Sponsored by Surgeons of Hope and Children&rsquo;s HeartLink, Dr. Ushay has worked as a cardiac intensivist in Cambodia, Africa, China and Nicaragua. </p>

Is Open Scheduling

Off

Audrey M. Uong

https://assets.montefioreeinstein.org/profiles/images/physphoto/Uong_Audrey_MD_420x504.jpg

First Name

Audrey

Last Name

Uong

NPI

1518387323

Faculty ID

15425

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Uong's&nbsp;clinical focus has been in pediatrics.

Research Focus

The care of hospitalized pediatric patients with asthma has been a main focus of research for Dr. Uong. She is also interested in researching the improvement of transitions of care in hospitalized pediatric patients.

Elsevier Profile

EMR ID

53070

Biography

<p>Audrey M. Uong, MD, is an Attending Physician, Division of Hospital Medicine at Children&rsquo;s Hospital at Montefiore (CHAM) and an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2019, her clinical focus has been in pediatrics.</p><p>In 2008, Dr. Uong received her Bachelor of Arts in Asian Languages and Civilizations from Amherst College. Her studies continued at New York Medical College, where she received her Doctor of Medicine in 2014. Following this, Dr. Uong continued her studies at Albert Einstein Medical College and received her Master of Science in Clinical Research Methods in 2019. She began her postgraduate training in 2014 with a 3-year internship and residency at Cohen Children&rsquo;s Medical Center. She then completed a fellowship in Pediatric Hospital Medicine at CHAM in 2019.</p><p>The care of hospitalized pediatric patients with asthma has been a main focus of research for Dr. Uong. She is also interested in researching the improvement of transitions of care in hospitalized pediatric patients. Her work has been published in numerous peer-reviewed journals and review articles, and has been presented nationally.</p><p>In 2019, Dr. Uong received the CHAM Research Day Oral Presentation Award, given to her from faculty judges for receiving top scores. Dr. Uong is board certified by the American Board of Pediatrics and is a member of numerous professional societies, including the American Academy of Pediatrics and the Academic Pediatric Association.</p>

Is Open Scheduling

Off

Alecia M. Thompson

https://assets.montefioreeinstein.org/profiles/images/Thompson_Alecia_MD_420x540.jpg

First Name

Alecia

Last Name

Thompson

NPI

1992930796

Faculty ID

12295

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

On

Professional Title

Research Focus

Dr. Thompson-Branch's research has focused on the role of cytokines in bronchopulmonary dysplasia and use of ultrasound to diagnose necrotizing enterocolitis.

Elsevier Profile

EMR ID

5397

Biography

<p>With an emphasis on general pediatrics and neonatology, Dr. Thompson completed her residency at NYU Medical Center in 2007 and fellowship at Yale-New Haven Hospital in 2010. During her fellowship, Dr. Thompson also audited the Robert Wood Johnson Clinical Scholars Program, with an interest in performing clinical research. Her research has focused on the role of cytokines in bronchopulmonary dysplasia and use of ultrasound to diagnose necrotizing enterocolitis. She plans to conduct research on the use of near-infrared spectroscopy to delineate central nervous system pathology in preterm infants and predict short-term neurologic outcomes.</p>

Is Open Scheduling

Off

Olena Slinchenkova

https://assets.montefioreeinstein.org/profiles/images/physphoto/Slinchenkova_Olena_MD_420x504.jpg

First Name

Olena

Last Name

Slinchenkova

NPI

1013205632

Faculty ID

14967

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55793

Is Open Scheduling

Off

Sumeet Singh-Tan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d41fe610-497e-11ec-8149-d1681d4b2362.jpg

First Name

Sumeet

Last Name

Singh-Tan

NPI

1215318001

Faculty ID

16569

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

14316

Is Open Scheduling

Off

Yang Shi

https://assets.montefioreeinstein.org/profiles/images/Shi_Yang_MD_2x.jpg

First Name

Yang

Last Name

Shi

NPI

1962714261

Faculty ID

14864

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol>
<li>Jui Choudhuri, <strong><span style="text-decoration: underline;">Yang Shi</span></strong> (2019). Skin Nodules in a 40-year-old Caribbean Man: What Can We Learn about Adult T-cell Leukemia/Lymphoma in the United States? <strong>American Society for Clinical Pathology Case Reports. </strong>April 2019.</li>
<li>Etan Marks, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>(2018). Duodenal-type Follicular Lymphoma: A Clinicopathologic Review. <strong>Archives of Pathology &amp; Laboratory Medicine </strong>142 (4): 542-547.</li>
<li><strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Evan Kulbacki, Endi Wang (2018). Delayed diagnosis of Type B Niemann-Pick Disease in a 31-year-old Caucasian woman. <strong>Hematopathology.</strong>1-4</li>
<li>Evan Himchak, Etan Marks, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Yanhua Wang (2018). Did I miss it? Discovering Hidden Co-existing Hematological Neoplasms: A Single Institutional Review of 100 Collision Tumors. <strong>International Journal of Surgical Pathology.</strong> 26(4):296-305</li>
<li><strong><span style="text-decoration: underline;">Yang Shi</span></strong> (2018). Chronic myeloid leukemia blast phase with erythroid differentiation in a twenty-year-old male patient presented with hematemesis. <strong>American Society for Clinical Pathology Case Reports. </strong>April 2018.</li>
<li>Etan Marks, Yanhua Wang, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Joseph Susa, Mark Jacobson, D. Yitzchak Goldstein (2018). Specific TCR Gene Rearrangements in Mycosis Fungoides: Does Advanced Clinical Stage Show A Preference? <strong>Journal of Clinical Pathology.</strong> 2018;71:1072-1077</li>
<li>Urvi Shah, Sengotuvel Viswanathan, Beamon Agarwal, Aditi Shastri, Ioannis Mantzaris, Murali Janakiram, Noah Kornblum, Ira Braunschweig, Amit K. Verma, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>, John F. Reinus, Olga Derman (2018). Sinusoidal-Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure. <strong>Case Reports in Oncological Medicine, </strong>Published online&nbsp;Dec 3, 2018&nbsp;</li>
<li>Etan Marks, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Yanhua Wang (2017). CD117 (KIT) is a Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma. <strong>Histopathology.</strong> 71(1):81-88.</li>
<li>Zhonghua Li, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>, John&nbsp;G.&nbsp;Pizzolo, and Yanhua Wang (2017). Utilization of Cytospin Slides in Flow Cytometry Laboratory: A Tool for Correlation of Morphology and Immunophenotype. <strong>Journal of Hematopathology.</strong> 10(2): 55-63.</li>
<li><strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Xiaoxian Zhao, Lisa Durkin, Heesun Joyce Rogers, Eric D Hsi (2016). Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. <strong>Human Pathology.</strong> 52:173-8</li>
<li><strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Andrew J Rand, Jennifer H Crow, Joseph O Moore, Anand S Lagoo (2015). Blast phase in chronic myelogenous leukemia (CML) is skewed towards unusual blast types in patients treated with tyrosine kinase inhibitors (TKIs): a comparative study of 67 cases.&nbsp; <strong>American Journal of Clinical Pathology. </strong>143(1):105-19.&nbsp;</li>
<li><strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Endi Wang (2014). Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review.&nbsp; <strong>Archives of Pathology &amp; Laboratory Medicine</strong>. 138(4):564-9.</li>
<li><span style="text-decoration: underline;"><strong>Yang Shi</strong></span>, Endi Wang (2015). Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review with an Emphasis on Diagnostic Differentiation from Other T-Cell/Natural Killer-Cell Neoplasms.&nbsp; Archives of Pathology &amp; Laboratory Medicine.&nbsp; 139(9):1173-80.&nbsp;</li>
<li>Miglena Komforti, <strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Maggie Stocker, Endi Wang (2014). Suspicious mammographic masses in the breast of a 65-year-old female: Splenosis in an unusual body site due to a remote ballistic trauma. <strong>British Journal of Haematology</strong>. 167(2):148</li>
<li><strong><span style="text-decoration: underline;">Yang Shi</span></strong>, Evan Kulbacki, David H.K. Chui, Endi Wang (2013). Gigantic splenomegaly in a 27-year-old male of South-East Asian descent with concurrent diagnosis of myeloproliferative neoplasm and hemoglobin H disease. <strong>European Journal of Haematology.</strong> 91(3):284-5.</li>
</ol>

EMR ID

77786

Is Open Scheduling

Off